NCT03258008 - Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 4, 2018

Primary Completion Date

November 5, 2021

Study Completion Date

November 5, 2021

Conditions

Malignant Neoplasms of Ill-defined Secondary and Unspecified SitesMalignant Neoplasms of Lip Oral Cavity and PharynxOropharyngeal Cancer

Interventions

DRUG

Utomilumab

Utomilumab given by vein on Cycle 1 Day 1. Cycle 1-2 100 mg, Cycle 3-12 50 mg until progressive disease, toxicity, or 1 yr.

BIOLOGICAL

ISA101b

ISA101b 100 mcg/peptide given subcutaneously every 4 weeks x 3 doses beginning cycle 1 day 1.

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston